<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02540759</url>
  </required_header>
  <id_info>
    <org_study_id>HC-NNHPD-213421</org_study_id>
    <nct_id>NCT02540759</nct_id>
  </id_info>
  <brief_title>Effect of Dose of Buglossoides Oil on EPA Accrual and on the Inflammatory Response</brief_title>
  <official_title>Study of the Effect of Dose of Buglossoides Arvensis Oil on Eicosapentaenoic Acid Accrual and on the Inflammatory Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Réseau de Santé Vitalité Health Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Réseau de Santé Vitalité Health Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of various doses of Buglossoides oil on the accrual of eicosapentaenoic acid (EPA)
      in blood and circulating cells will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma eicosapentaenoic concentration (EPA)</measure>
    <time_frame>Day 28</time_frame>
    <description>Expressed as μmol/L plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma 20:4n-3</measure>
    <time_frame>Day 28</time_frame>
    <description>Expressed as μmol/L plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma docosapentaenoic acid (DPA)</measure>
    <time_frame>Day 28</time_frame>
    <description>Expressed as μmol/L plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma 20:4n-3, EPA and DPA individually as % of total fatty acids</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mononuclear cell 20:4n-3, EPA and DPA individually as % of total fatty acids</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: glucose</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: calcium</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: sodium</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: potassium</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: blood urea nitrogen</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: creatinine</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: alkaline phosphatase</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: aspartate aminotransferase</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: gamma-glutamyltransferase</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: total bilirubin</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: amylase</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: uric acid</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: albumin</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology: white blood cell count</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology: neutrophil count</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology: red blood cell count</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology:hemoglobin</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology: hematocrit</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology: platelet count</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood lipid profile: triglycerides</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood lipid profile: total cholesterol</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood lipid profile: low density lipoprotein cholesterol (LDL-c)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood lipid profile: non-high density lipoprotein-cholesterol (non-HDL-c)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood lipid profile: HDL-c</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum chemistry: chloride</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: mean corpuscular volume</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: mean corpuscular hemoglobin</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: mean corpuscular hemoglobin concentration</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: red cell distribution width</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: mean platelet volume</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: lymphocyte concentration</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: monocyte count</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: eosinophil count</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: basophil count</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: Immature granulocytes count</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: immature granulocytes (% white blood cell (WBC))</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: neutrophil (% WBC)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: lymphocyte (% WBC)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: monocytes (% WBC)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: eosinophil (% WBC)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting hematology profile: basophil (% WBC)</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis: appearance</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis: density</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis: leukocyte esterase</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis: nitrites</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis: pH</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis: protein</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis: glucose</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis: acetone</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis: blood</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis: urobilinogen</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cytokine production following ex vivo stimulation: interferon-gamma</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine production following ex vivo stimulation: interleukin-1beta</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine production following ex vivo stimulation: interleukin-6</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine production following ex vivo stimulation: interleukin-8</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine production following ex vivo stimulation: interleukin-10</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine production following ex vivo stimulation: interleukin-17A</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine production following ex vivo stimulation: interleukin-23</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine production following ex vivo stimulation: monocyte chemoattractant protein-1</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cytokine production following ex vivo stimulation: tumor necrosis factor-alpha</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>High oleic sunflower oil (HOSO)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 ml HOSO/day in a single dose, 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose Buglossoides oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 ml Buglossoides oil/day in a single dose, 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose Buglossoides oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 ml Buglossoides oil + 4 ml HOSO/day in a single dose, 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Buglossoides oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 ml Buglossoides oil + 7 ml HOSO/day in a single dose, 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Buglossoides oil</intervention_name>
    <arm_group_label>High dose Buglossoides oil</arm_group_label>
    <arm_group_label>Medium dose Buglossoides oil</arm_group_label>
    <arm_group_label>Low dose Buglossoides oil</arm_group_label>
    <other_name>Ahiflower</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Oleic Sunflower Oil</intervention_name>
    <arm_group_label>High oleic sunflower oil (HOSO)</arm_group_label>
    <arm_group_label>Medium dose Buglossoides oil</arm_group_label>
    <arm_group_label>Low dose Buglossoides oil</arm_group_label>
    <other_name>HOSO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or non-pregnant women, using an effective form of birth control (such as oral
             contraceptives, injectable contraceptives or the barrier method such as a intrauterine
             device (IUD) with a spermicide, a diaphragm with a spermicide, a condom with a
             spermicide or a sponge with a spermicide) for at least 3 months prior to entry into
             the study and continuing during participation in the study.

          2. 18 to 65 years of age, inclusive.

          3. Body mass index (BMI) 18 - 39.9 kg/m2

          4. Subject is willing to avoid alcohol consumption for 24h prior to every clinic visit.

          5. The subject will not modify smoking habits during supplementation period.

          6. No significant medical conditions that in the opinion of the qualified physician,
             would preclude the subject's participation in the study.

          7. Signed informed consent.

          8. Willing to follow all study procedures including study visits, fasting blood draws,
             stable body weight, normal eating habits, current activity level, and compliance with
             study preparation.

          9. Willing to not consume fish, crustaceans and shellfish for the duration of the study.

        Exclusion Criteria:

          1. Pregnancy or lactation. Women trying to conceive. Women who will try to conceive who
             are unwilling to commit to the use of a medically approved form of contraception
             throughout the study period. Method of contraception must be recorded in the case
             report file.

          2. Individual has a condition the study physician believes would interfere with the
             participant's ability to provide informed consent, comply with his responsibilities
             during the study, which might confound the interpretation of the study results or put
             the person at undue risk.

          3. Medical conditions including an active peptic ulcer, inflammatory bowel disease, or
             gastrointestinal bleeding and any medical condition or prior gastrointestinal surgery
             that could influence absorption, metabolism or excretion of the study supplement.

          4. History or presence of significant, renal, hepatic, gastrointestinal, pulmonary,
             biliary, neurological or endocrine disorders.

          5. History or presence of cancer in the past 2 yrs, except for non-melanoma skin cancers
             (e.g. basal or squamous cell carcinoma of the skin).

          6. Clinically significant abnormal laboratory test results including but not limited to
             LDL-cholesterol ≥ 4.1mM, triglyceride levels ≥3.95mM, fasting creatinine ≥ 1.5 mg/dL,
             alanine transaminase or aspartate aminotransferase ≥ 1.5X the upper limit of normal.

          7. Currently being treated for angina, arrhythmia and/or congestive heart failure.
             History of myocardial infarction or stroke.

          8. Uncontrolled hypertension (resting systolic blood pressure ≥ 160 mmHg or diastolic
             blood pressure ≥ 100 mmHg).

          9. Type 1 or 2 diabetes. Fasting glucose ≥ 100 mg/dL. HbA1c ≥ 6.0.

         10. If a smoker, subject smokes no more than 1 pack (20 cigarettes) daily.

         11. History (within 12 months) or current alcohol or substance abuse (no more than 14
             consumptions per week; 1 consumption= 12 oz beer, 5 oz wine, 1.5 oz distilled
             spirits).

         12. Use of any lipid-altering medications (statins, bile acid sequestrants, cholesterol
             absorption inhibitors, fibrates, over the counter and prescription formulations of
             niacin).

         13. Unstable use of thyroid medication. Stable, treated hypothyroidism is not an exclusion
             criteria.

         14. Use of any weight loss or lipid metabolism medication/supplement/program (including
             lipase inhibitors) within 1 month of study period OR weight gain or loss &gt; 2 kg in the
             past 3 months.

         15. Currently taking fish oil or any other omega-3 or omega-6 polyunsaturated fatty acids
             (PUFA) supplement/drug within one month of Visit 1 and throughout the study.
             Consumption of fatty fish (salmon, herring, mackerel, albacore tuna, and sardines)
             more than 2X a month within one month of visit 1 and throughout the study period.
             Consumption (more than twice a month) of any EPA/DHA enriched foods (e.g.
             docosahexaenoic acid (DHA)-enriched eggs) within one month of Visit 1. Unwillingness
             to avoid all fish including shellfish and crustaceans throughout the study period.

         16. Use of alpha-linolenic acid-containing seeds and oils such as flax seed, chia seed,
             perilla seed, hemp, spirulina, walnut, mustard seed or black currant seeds/oil within
             one month of Visit 1 and throughout the study.

         17. Use of an investigational product within the previous 30 days.

         18. Has donated blood up to 4 weeks before the start of the study. Not willing to cease
             being a blood donor during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Surette, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Moncton, Moncton, NB, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université de Moncton</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1A 3E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>March 10, 2016</last_update_submitted>
  <last_update_submitted_qc>March 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Buglossoides arvensis</keyword>
  <keyword>vegetable oil</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>participants</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

